GlassScriptPhysician profile
Walter J Duffy
NPI 1093853368
$45,880.94
in general payments reported to CMS, 2019-2025
48 companies · $2,369 in 2025
The $2,369 reported for 2025 was more than what 91% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $27K · 2020: $227 · 2021: $1,627 · 2022: $2,967 · 2023: $3,487 · 2024: $8,403 · 2025: $2,369.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,338 · Honoraria: $5,200 · Travel and Lodging: $895 · Consulting Fee: $480 · Education: $346.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,338.36 |
| Honoraria | $5,200.00 |
| Travel and Lodging | $895.46 |
| Consulting Fee | $480.00 |
| Education | $345.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $9,777.44 | 2019-2025 | Aristada, Lybalvi |
| Ironshore Pharmaceuticals INC. | $9,629.14 | 2019-2023 | Jornay Pm |
| Livanova USA, INC. | $7,024.25 | 2021-2024 | Vns Therapy Symmetry Model 8103 Generator, Thn Sleep Therapy |
| Neurocrine Biosciences, INC. | $6,044.16 | 2019-2022 | |
| Allergan, INC. | $2,510.85 | 2019-2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,566.11 | 2021-2025 | Caplyta |
| Jazz Pharmaceuticals INC. | $1,478.85 | 2019-2025 | |
| Otsuka America Pharmaceutical, INC. | $1,220.78 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Abbvie INC. | $1,219.59 | 2021-2023 | Vraylar |
| Corium, LLC | $1,146.89 | 2022-2025 | Azstarys |
| Supernus Pharmaceuticals, INC. | $784.02 | 2021-2025 | Qelbree, Qelbree |
| Axsome Therapeutics, INC. | $613.27 | 2022-2025 | Auvelity, Sunosi |
| Janssen Pharmaceuticals, INC | $576.31 | 2019-2025 | Invega Sustenna |
| Teva Pharmaceuticals USA, INC. | $520.86 | 2021-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Harmony Biosciences LLC | $451.99 | 2022-2025 | Wakix |
Show all 37 companies
11 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Walter Duffy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.